PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 198 filers reported holding PDL BIOPHARMA INC in Q1 2016. The put-call ratio across all filers is 1.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,511 | 0.0% | 612 | 0.0% | 0.00% | – |
Q1 2024 | $1,511 | 0.0% | 612 | 0.0% | 0.00% | – |
Q4 2023 | $1,511 | 0.0% | 612 | 0.0% | 0.00% | – |
Q3 2023 | $1,511 | 0.0% | 612 | 0.0% | 0.00% | – |
Q2 2023 | $1,511 | -99.8% | 612 | -99.7% | 0.00% | -100.0% |
Q3 2020 | $621,000 | -5.3% | 197,055 | -12.5% | 0.00% | 0.0% |
Q2 2020 | $656,000 | +5.0% | 225,328 | +1.6% | 0.00% | 0.0% |
Q1 2020 | $625,000 | -8.9% | 221,807 | +4.9% | 0.00% | 0.0% |
Q4 2019 | $686,000 | +50.1% | 211,460 | -0.1% | 0.00% | 0.0% |
Q3 2019 | $457,000 | -26.1% | 211,696 | +7.6% | 0.00% | 0.0% |
Q2 2019 | $618,000 | -23.2% | 196,661 | -9.1% | 0.00% | -50.0% |
Q1 2019 | $805,000 | +28.4% | 216,377 | +0.1% | 0.00% | +100.0% |
Q4 2018 | $627,000 | +52.6% | 216,199 | +38.4% | 0.00% | 0.0% |
Q3 2018 | $411,000 | +11.4% | 156,246 | -0.9% | 0.00% | 0.0% |
Q2 2018 | $369,000 | -24.1% | 157,596 | -4.6% | 0.00% | 0.0% |
Q1 2018 | $486,000 | +3.6% | 165,200 | -3.5% | 0.00% | 0.0% |
Q4 2017 | $469,000 | -33.6% | 171,116 | -17.9% | 0.00% | -50.0% |
Q3 2017 | $706,000 | +39.0% | 208,346 | +1.3% | 0.00% | +100.0% |
Q2 2017 | $508,000 | +5.4% | 205,750 | -3.1% | 0.00% | 0.0% |
Q1 2017 | $482,000 | +10.6% | 212,350 | +3.2% | 0.00% | 0.0% |
Q4 2016 | $436,000 | -39.0% | 205,782 | -3.6% | 0.00% | -50.0% |
Q3 2016 | $715,000 | +6.9% | 213,485 | +0.1% | 0.00% | 0.0% |
Q2 2016 | $669,000 | -24.7% | 213,205 | -20.2% | 0.00% | -33.3% |
Q1 2016 | $889,000 | +4.0% | 267,106 | +10.6% | 0.00% | 0.0% |
Q4 2015 | $855,000 | -25.7% | 241,491 | +5.5% | 0.00% | -25.0% |
Q3 2015 | $1,151,000 | -19.0% | 228,911 | +3.6% | 0.00% | -20.0% |
Q2 2015 | $1,421,000 | +12.1% | 221,051 | +22.6% | 0.01% | +25.0% |
Q1 2015 | $1,268,000 | +11.7% | 180,251 | +22.5% | 0.00% | +33.3% |
Q4 2014 | $1,135,000 | +2.0% | 147,176 | -1.2% | 0.00% | 0.0% |
Q3 2014 | $1,113,000 | -51.3% | 148,945 | -36.9% | 0.00% | -57.1% |
Q2 2014 | $2,286,000 | +19.2% | 236,145 | +2.3% | 0.01% | +16.7% |
Q1 2014 | $1,918,000 | +55.1% | 230,829 | +57.5% | 0.01% | +50.0% |
Q4 2013 | $1,237,000 | +5.6% | 146,549 | -0.3% | 0.00% | 0.0% |
Q3 2013 | $1,171,000 | +2.4% | 146,969 | -0.7% | 0.00% | 0.0% |
Q2 2013 | $1,143,000 | – | 148,061 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |